Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2016

View Archived Issues

EMA issues positive opinion on the MAA for SomaKit TOC

Heidelberg Pharma signs option agreement with the Max Delbruck Center for BCMA antibodies

Enrollment open in phase I trial of HS-10241 in solid tumors

Grant supports Garvan Institute of Medical Research's purchase of Chromium Genome Solution

Shanghai Institute Materia Medica patents anticancer agents

Phase II study of CMV vaccine ASP-0113 in kidney transplant patients does not meet primary endpoint

FDA approves Kyleena for prevention of pregnancy for up to 5 years

KemPharm submits IND application to commence clinical trials of KP-415

Eli Lilly discloses GPR142 agonists

Bristol-Myers Squibb and Rigel Pharmaceuticals describe TGF-beta1 inhibitors

PRIDE-HD study demonstrates statistically significant impact on disease progression at 52 weeks

Evgen's SFX-01 shows promise in preclinical MS model

SUSTAIN-6 finds reduced cardiovascular outcomes with semaglutide in type 2 diabetes patients

Prexton Therapeutics completes phase I study of lead compound for Parkinson's disease

Siponimod reduces the risk of MS disability progression

ARN-6039 safe in phase I trial

FDA grants accelerated approval to Exondys 51 for Duchenne muscular dystrophy

XOMA updates status of phase II trials of XOMA-358 in severe hypoglycemia

Testing of IRX-4204 in preclinical MS model shows promising results

NovaBay Pharmaceuticals' Auriclosene Irrigating Solution shows positive results in phase IIb study

FDA grants fast track designation to SELLAS' galinpepimut-S

PSP/reg shows promise as an assistive biomarker for the diagnosis of DN

GUB09-145 exerts marked effects on HbA1c, body weight and glucose homestasis in mice

FDA awards fast track status to Aerosurf for RDS

BioArctic and AbbVie collaborate on Parkinson's disease

Cantargia outlines plans for CAN-04 development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...